Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Making sense of antisense.

B R Yacyshyn¹, W R Shanahan

¹Division of Gastroenterology, University of Alberta, Edmonton. bruce.yacyshyn@ualberta.ca

Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie

|January 14, 2000

Summary

DNA antisense oligonucleotides offer unique therapeutic potential for controlling human gene translation. This technology shows promise for laboratory applications and developing highly specific drugs, including for Crohn's disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

New biotechnological therapies for Crohn's disease: where are we now?

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007

Same author

ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1.

Expert opinion on investigational drugs·2005

Same author

Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.

Clinical and experimental immunology·2005

Same author

The clinical importance of proton pump inhibitor pharmacokinetics.

Digestion·2002

Same author

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

Alimentary pharmacology & therapeutics·2002

Same author

Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to intracellular adhesion molecule-1 in the HLA-B27/beta2 microglobulin transgenic rat model.

The Journal of pharmacology and experimental therapeutics·2002

Area of Science:

Molecular Biology
Genetics
Pharmacology

Background:

The DNA double helix structure enables gene targeting for therapies.
Antisense mechanisms are naturally used by organisms like viruses to regulate gene replication.
The potential of DNA as a therapeutic agent has been recognized.

Purpose of the Study:

To review the application of DNA antisense oligonucleotides in human gene translation control.
To discuss the use of systemically administered oligonucleotides in Crohn's disease.
To explore the conceptualization and future directions of DNA antisense technology.

Main Methods:

Review of existing scientific literature and case reports.
Analysis of systemically administered oligonucleotide therapy.
Exploration of DNA antisense mechanisms in gene regulation.

Main Results:

DNA antisense oligonucleotides can be used to control human gene translation.
Systemic administration of oligonucleotides has been reported in human Crohn's disease.
This technology presents unique laboratory and therapeutic drug applications.

Conclusions:

DNA antisense oligonucleotides represent a significant advancement in molecular medicine.
The technology holds promise for developing highly specific therapeutic drugs.
Further research into DNA antisense compounds could lead to novel treatments.

Related Experiment Videos